Drugs / Human Amniotic Epithelial Stem Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04414813 | Oct 2020 → Feb 2023 | Parkinson disease | Shanghai East Hospital | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06444022 | Jun 2026 → Dec 2027 | acute graft versus host disease | Nanfang Hospital, Southern Medical University | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human amniotic epithelial stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06444022 ↗ |
| Known as | hAESCs | “Human amniotic epithelial stem cells（hAESCs）” NCT06444022 ↗ |
| Route | Other | “hAESCs will be accurately transplanted into the lateral ventricle.” NCT04414813 ↗ |